Brief: AstraZeneca Says SERENA-4 Phase III Trial Of Etcamah With Palbociclib Does Not Meet Primary Endpoint
11/09/2026 21:39
BRIEF-AstraZeneca Says SERENA-4 Phase III Trial Of Etcamah With Palbociclib Does Not Meet Primary Endpoint Sept 11 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA - SERENA-4 PHASE III TRIAL OF ETCAMAH WITH PALBOCICLIB DOES NOT MEET PRIMARY ENDPOINT
ASTRAZENECA - REPORTS NO NEW SAFETY CONCERNS FOR ETCAMAH WITH PALBOCICLIB IN SERENA-4 TRIAL
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines